medigraphic.com
Colegio de Medicina Interna de México.

2015, Number 2

<< Back Next >>

Med Int Mex 2015; 31 (2)

Antecedentes: las concentraciones séricas de CKBB se incrementan rápidamente posterior a daño cerebral y pueden alcanzar 30 a 40 veces por arriba del valor control. Se considera factor diagnóstico y pronóstico en pacientes con mediciones seis horas poster

Gracia-Reyes C, Dávila-Sosa D, Rodríguez-Romero E, Castro-Serna D, Melchor-López A

Language: Spanish
References: 22
Page: 145-149
PDF size: 422.47 Kb.


ABSTRACT

Background: Serum CKBB apparently increases rapidly after the brain damage and can reach 30-40 times above the control value. It has come to regard as a diagnostic and prognostic factor in patients with measurements 6 hours after the injury and then at 6 days. It is proposed an enzymatic marker to guide us to early diagnosis and final treatment of this disease.
Objective: To determine whether serum levels of CKBB › 22 IU/L allow the diagnosis of cerebral ischemic vascular disease.
Material and method: A prospective study in which 43 patients with diagnosis of ischemic stroke less than 12 hours were included; all were submitted to a determination of serum CKBB and cranial computed tomography scans on admission and at 72 hours. It was calculated sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV), as well as ROC curves for determining cutoff CKBB and performing relative risk.
Results: Of the patients included, 53.4% were male, with a mean age of 59.4±19 years, 35% of patients had not comorbidities. In the comparison of the evaluated test with the reference test (cranial CT) sensitivity 38%, specificity 89%, PPV 80%, NPV 60% were obtained. With the area under the curve of 93% and OR 6.1.
Conclusions: A negative test of CK BB (‹22 IU/L) is useful to exclude the diagnosis of ischemic cerebral vascular disease.


REFERENCES

  1. Arauz A, Ruiz-Franco A. Enfermedad vascular cerebral. Revista de la Facultad de Medicina, UNAM 2012;55.

  2. Young LT, Joffe R. Cerebrovascular diseases. Principles of neurology. McGraw Hill, 1998;1-5.

  3. Chiquete E, Ruiz J, Murillo B, et al. Mortalidad por enfermedad vascular cerebral en México, 2000-2008: Una exhortación a la acción. Rev Mex Neuroci 2011;12:235-241.

  4. Cabrera-Rayo A, Martínez-Olazo O, Laguna-Hernández G. Epidemiología de la enfermedad cerebral en hospitales de la ciudad de México. Estudio metacéntrico. Med Int Méx 2006;24:98-103.

  5. Ávila-Saldívar MN, Ordóñez-Cruz AE. Enfermedad vascular cerebral: incidencia y factores de riesgo en el Hospital General La Perla. Med Int Méx 2012;28:342-344.

  6. U KothariR, Barsan W. Tratamiento de accidente apopléjico. Medicina de urgencias. México: McGraw-Hill, 1998;1-5.

  7. Fauci A, Braunwald E, Isselbacher K, et al. Enfermedades cerebrovasculares. Harrison principios de medicina interna. México: McGraw-Hill Interamericana, 2012;2:2644-2680.

  8. Ramiro HM, Santiago ADI. Enfermedad vascular cerebral. El internista. México: McGraw-Hill Interamericana, 1999;733-756.

  9. Rooze MI, Kaasik AE. Enzymatic activity of the cerebroespinal fluid in patients with cerebral infarct. Zh Nevropatol Psikhiatr Im Ss Korsakova 1998;88:18-21.

  10. Coplin WM, Longstreth WT, Lam Am, Chandler WL, et al. Cerebroespinal fluid creatin kinase-BB isoenzyme activity and outcome after subarachnoid hemorrhage. Arch Neurol 1999;56:1348-1352.

  11. Zarghami N, Giai M, Yu H, Roagna R, et al. Creatine kinasa BB isoenzyme levels in tumour cytosals and survival of breast cancer patients. Br J Cancer 1996;73:386-390.

  12. Nussinovith M, Klinger G, Soen G, Magazanik A, et al. Increased creatine kinasa isoenzyme concentration in cerebrospinal fluid with meningitis. Clin Pediatr 1996;35:349-351.

  13. Aksenova MV, Aksenov MY, Payne RM, Trojanowski JQ, et al. Oxidation of cytosolic proteins and expression of creatine kinase BB in frontal lobe different neurodegenerative disorders. Dement Geriatr Cogn Disord 1999;10:158-165.

  14. Hulley SB, Cummings SR. Diseño de la investigación clínica. Un enfoque epidemiológico. Madrid: Hacourt Brace de España, 1997;13:232-233.

  15. Alwan A. Global status report noncommunicable diseases 2010. Geneva: World Health Organization 2011.

  16. García S, Villagómez AJ. Enfermedad vascular cerebral. Actualidades en Medicina Interna, 1998;5:2-16.

  17. Pfeiffer FE, Hamburger HA, Yanagihara T. Creatine kinase BB isoenzyme in CSF in neurologic diseases. Measurement by radioimmunoassay. Arch Neurol 1983;40:169-172.

  18. Corca M, Kloss R, Stober T, Schimrigk K, Keller HE. Elevated serum CK-BB levels in patients with cerebral transtentorial herniation after ischemic stroke. Clin Biochem 1989;22:131-134.

  19. Kloss R, Keller HE, Stober T, Emde H, Schimrighk K. Creatine kinase BB activity in the serum of patients with cerebrovascular diseases. Nervenarzt 1985;23:16-18.

  20. Coplin WM, Longstreth Jr WT. Cerebroespinal fluid creatine kinase-BB isoenzyme activity and outcome after subarachnoid hemorrhage. Arch Neurol 1999;36:1348-1352.

  21. Phillips JP, Jones HM, Hitchcock R. Radioimmunoassay of serum creatine kinase BB as index of brain damage after head injury. Br Med J 1980;281:777-779.

  22. Kaste M, Sommer H. Brain-type creatine kinase isoenzyme occurrence in serum in acute cerebral disorders. Arch Neurol 1977;34:142-144.




2020     |     www.medigraphic.com